Sinopharm Group Co (HKSE:01099) Construction In Progress : HK$790 Mil (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Construction In Progress?

Sinopharm Group Co's quarterly construction in progress declined from Dec. 2023 (HK$553 Mil) to Jun. 2024 (HK$0 Mil) but then increased from Jun. 2024 (HK$0 Mil) to Dec. 2024 (HK$790 Mil).

Sinopharm Group Co's annual construction in progress declined from Dec. 2022 (HK$893 Mil) to Dec. 2023 (HK$553 Mil) but then increased from Dec. 2023 (HK$553 Mil) to Dec. 2024 (HK$790 Mil).

Sinopharm Group Co Construction In Progress Historical Data

The historical data trend for Sinopharm Group Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Construction In Progress Chart

Sinopharm Group Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Construction In Progress

Get a 7-Day Free Trial

616.24

879.82

893.43

552.87

789.88

Sinopharm Group Co Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Construction In Progress	Get a 7-Day Free Trial															893.43	-	552.87	-	789.88

Sinopharm Group Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Sinopharm Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (HKSE:01099) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

SHTDY:USA SHTDF:USA X2S:Germany

Address

No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website

http://www.sinopharmgroup.com.cn

Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Executives

Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Citic Securities Company Limited	2201 Interest of corporation controlled by you
Zhong Xin Zheng Quan Yun Fan Dan Yi Zi Chan Guan Li Ji Hua	2501 Other
Zhong Xin Zheng Quan Zi Chan Guan Li You Xian Gong Si	2102 Investment manager
Lazard Asset Management Llc	2102 Investment manager
Citigroup Inc.	2502 Approved lending agent
Fmr Llc	2201 Interest of corporation controlled by you
Blackrock, Inc.	2201 Interest of corporation controlled by you

Sinopharm Group Co Headlines

No Headlines